Collegium Pharmaceutical (COLL) EBT (2014 - 2026)

Collegium Pharmaceutical's EBT history runs 13 years deep, the most recent figure standing at $18.7 million for Q1 2026.

• In Q1 2026, EBT rose 500.26% year-over-year to $18.7 million; the TTM figure through Mar 2026 stood at $108.2 million (up 66.34% YoY), while the FY2025 annual figure was $92.6 million, down 6.04% from the prior year.
• EBT was $18.7 million for Q1 2026 at Collegium Pharmaceutical, down from $29.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $46.7 million in Q4 2023 to a low of -$17.6 million in Q1 2023.
• Historically, EBT has averaged $15.1 million across 5 years, with a median of $17.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: EBT slumped 202.38% in 2022, then jumped 1909.99% in 2023.
• A 5-year view of EBT shows it stood at -$7.8 million in 2022, then soared by 699.54% to $46.7 million in 2023, then slumped by 63.03% to $17.3 million in 2024, then jumped by 68.14% to $29.0 million in 2025, then sank by 35.46% to $18.7 million in 2026.
• The last three EBT figures came in at $18.7 million (Q1 2026), $29.0 million (Q4 2025), and $43.4 million (Q3 2025), per Business Quant data.